Earnings
Travere's Departing CEO Says New IgAN Drugs Will Be Add-Ons To Filspari, Not Replacements
Eric Dube said switching away from Filspari has not changed, as third-quarter IgAN patient starts slipped from the second quarter.
TVTX
Travere Therapeutics (TVTX) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
Travere's Outgoing CEO Exit Carries A $31.3 Million Equity Charge, With $26.9 Million Still To Come
Most of the cost of changes to Eric Dube's stock awards lands in the fourth quarter, after FILSPARI sales rose to $200.2 million.
Earnings
Travere's Filspari Sales Climb 120% To $200.2 Million, Yet A $113.1 Million Licensing Charge Drives A Loss
The kidney-drug maker posted a $52.3 million third-quarter net loss against a $25.7 million profit a year earlier.